康芝药业
(300086)
| 流通市值：38.52亿 | | | 总市值：39.78亿 |
| 流通股本：4.41亿 | | | 总股本：4.55亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 326,382,078.2 | 232,448,515.1 | 112,416,086.22 | 472,817,734.83 |
| 营业收入 | 326,382,078.2 | 232,448,515.1 | 112,416,086.22 | 472,817,734.83 |
| 二、营业总成本 | 454,805,398.28 | 302,106,524.19 | 126,233,165.07 | 643,150,239.2 |
| 营业成本 | 152,213,016.72 | 107,540,967.99 | 54,847,284.95 | 211,084,593.76 |
| 税金及附加 | 9,630,336.01 | 5,940,538.16 | 2,751,268.23 | 13,163,194.11 |
| 销售费用 | 179,143,135.32 | 116,211,532.39 | 33,568,194.79 | 262,699,679.67 |
| 管理费用 | 84,675,602.99 | 55,341,975.52 | 27,717,381.66 | 116,627,969.25 |
| 研发费用 | 15,438,816.8 | 8,874,961.73 | 2,848,491.65 | 19,052,679.06 |
| 财务费用 | 13,704,490.44 | 8,196,548.4 | 4,500,543.79 | 20,522,123.35 |
| 其中:利息费用 | 12,696,141.63 | 8,324,962.66 | 4,563,751.17 | 21,069,939.46 |
| 其中:利息收入 | 192,861.48 | 184,450.19 | 93,477 | 828,917.89 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | - | -18,137,228.53 |
| 加:投资收益 | - | - | - | 16,688,228.22 |
| 资产处置收益 | 469,410.71 | 455,864.28 | 461,122.72 | -228,016.41 |
| 资产减值损失(新) | 1,311,574.79 | -2,678,657.13 | 1,890,133.49 | -59,527,499.15 |
| 信用减值损失(新) | 9,937,505.59 | 7,441,671.98 | -272,052.74 | -1,530,328.1 |
| 其他收益 | 4,799,662.33 | 3,749,432.85 | 1,681,050.32 | 10,720,335.81 |
| 四、营业利润 | -111,905,166.66 | -60,689,697.11 | -10,056,825.06 | -222,347,012.53 |
| 加:营业外收入 | 453,992.16 | 378,746.6 | 68,219.49 | 1,039,426.73 |
| 减:营业外支出 | 385,513.6 | 307,914.32 | -37,283.7 | 10,663,252 |
| 五、利润总额 | -111,836,688.1 | -60,618,864.83 | -9,951,321.87 | -231,970,837.8 |
| 减:所得税费用 | -13,713,052.48 | -5,510,515.08 | 304,820.82 | -7,544,331.79 |
| 六、净利润 | -98,123,635.62 | -55,108,349.75 | -10,256,142.69 | -224,426,506.01 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -98,123,635.62 | -55,108,349.75 | -10,256,142.69 | -224,426,506.01 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -96,611,496.44 | -54,081,719.36 | -9,691,696.26 | -216,208,517.94 |
| 少数股东损益 | -1,512,139.18 | -1,026,630.39 | -564,446.43 | -8,217,988.07 |
| 扣除非经常损益后的净利润 | -98,634,570.11 | -56,007,110.23 | -10,711,474.9 | -213,100,665.04 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.21 | -0.12 | -0.02 | -0.47 |
| (二)稀释每股收益 | -0.21 | -0.12 | -0.02 | -0.47 |
| 八、其他综合收益 | - | - | - | -252,137.11 |
| 归属于母公司股东的其他综合收益 | - | - | - | -252,137.11 |
| 九、综合收益总额 | -98,123,635.62 | -55,108,349.75 | -10,256,142.69 | -224,678,643.12 |
| 归属于母公司股东的综合收益总额 | -96,611,496.44 | -54,081,719.36 | -9,691,696.26 | -216,460,655.05 |
| 归属于少数股东的综合收益总额 | -1,512,139.18 | -1,026,630.39 | -564,446.43 | -8,217,988.07 |
| 公告日期 | 2025-10-27 | 2025-08-28 | 2025-04-29 | 2025-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |